Samples that are negative for molecular markers should undergo sequencing for the detection of other common biologically relevant mutations in AML including FLT3, KIT, RUNX1, DNMT3A, IDH1, TET2, and ASXL1. Next-generation sequencing (NGS) could possibly identify novel genetic markers in a population specific group and add further value to the results generated by AMLprofiler [19, 20]. The gene discussed is FLT3; the disease is acute myeloid leukemia.